{
  "id": "breast-biomarker",
  "display_name": "Breast Cancer Biomarker Testing",
  "cohort": "Breast Cancer, Biomarker Testing Compliance (2024–2025)",
  "insight_type": "Precision Medicine Utilization",
  "summary": "Breast cancer biomarker testing averages 83% compliance, with strong ER/PR/HER2 testing but opportunities in expanded panel testing for PIK3CA, BRCA1/2, and PDL1.",
  "chart": {
    "type": "bar",
    "unit": "biomarker",
    "data": [
      { "name": "ER", "value": 98, "gap": 8, "highlight": false },
      { "name": "PR", "value": 98, "gap": 8, "highlight": false },
      { "name": "HER2", "value": 95, "gap": 5, "highlight": false },
      { "name": "PIK3CA", "value": 72, "gap": -18, "highlight": true },
      { "name": "BRCA1/2", "value": 68, "gap": -22, "highlight": true },
      { "name": "PDL1", "value": 65, "gap": -25, "highlight": true }
    ],
    "benchmark": 90,
    "nccn_target": 95
  },
  "financial_impact": {
    "annual_opportunity": "$185,000/year",
    "math": "$185,000/year = 21% avg testing gap (advanced markers) × 32 eligible patients × $27,500 precision therapy value"
  },
  "clinical_impact": {
    "description": "Advanced breast cancer biomarker testing improves treatment selection and patient outcomes.",
    "metrics": [
      {
        "type": "PFS",
        "value": "+6.3 months",
        "description": "Improved progression-free survival with matched therapies"
      },
      {
        "type": "OS",
        "value": "+7.8 months",
        "description": "Overall survival benefit with biomarker-guided treatment"
      },
      {
        "type": "ORR",
        "value": "+28%",
        "description": "Higher objective response rate with matched therapies"
      },
      {
        "type": "QoL",
        "value": "+22%",
        "description": "Improved quality of life scores"
      },
      {
        "type": "TTF",
        "value": "-42%",
        "description": "Reduced time to treatment failure"
      }
    ],
    "quantitative": "+7.8 months OS"
  },
  "peer_comparison": {
    "description": "Leading breast cancer programs achieve >90% comprehensive biomarker testing compliance including expanded molecular panels.",
    "peer_benchmark": 90,
    "financial_impact": {
      "annual_opportunity": "$240,000/year",
      "math": "$240,000/year = 24% gap to peer benchmark × 36 patients × $27,800 improved care value"
    },
    "action_steps": [
      {
        "text": "Implement expanded biomarker reflex panel for metastatic breast cancer",
        "icon": "document"
      },
      {
        "text": "Create PIK3CA testing protocol for HR+/HER2- patients",
        "icon": "clipboard"
      },
      {
        "text": "Develop automated BRCA1/2 testing algorithm",
        "icon": "cog"
      },
      {
        "text": "Establish breast-specific molecular tumor board",
        "icon": "users"
      }
    ]
  },
  "weighted_score": 88,
  "action_steps": [
    {
      "text": "Implement comprehensive NGS panel for all metastatic breast cancer",
      "icon": "document"
    },
    {
      "text": "Create provider education on PIK3CA and BRCA testing indications",
      "icon": "users"
    },
    {
      "text": "Develop PDL1 testing algorithm for triple-negative breast cancer",
      "icon": "clipboard"
    },
    {
      "text": "Establish biomarker testing KPI tracking by provider",
      "icon": "chart"
    }
  ],
  "suggestions": [
    {
      "text": "Consider germline testing pathway for hereditary risk",
      "icon": "clipboard"
    },
    {
      "text": "Evaluate HRD testing implementation pathway",
      "icon": "search"
    }
  ],
  "drilldowns": [
    {
      "label": "By Provider",
      "cohort": "Breast Cancer Testing by Provider",
      "jsonFile": "breast-biomarker-by-provider.json",
      "drilldownLevel": 3
    },
    {
      "label": "By Testing Method",
      "cohort": "Breast Cancer Testing by Method",
      "jsonFile": "breast-biomarker-by-method.json",
      "drilldownLevel": 3
    },
    {
      "label": "All Biomarkers",
      "cohort": "Biomarker Testing by Cancer Type",
      "jsonFile": "biomarker-compliance-by-cancer.json",
      "drilldownLevel": 1
    },
    {
      "label": "Overall Compliance",
      "cohort": "Biomarker Testing Compliance",
      "jsonFile": "biomarker-compliance.json",
      "drilldownLevel": 0
    }
  ]
} 